SCHEMBL4722708

SCHEMBL4722708

CCCCOc1on[c]c1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.40
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
CYP2C9 P11712 8/20 0.39
CYP2C19 P33261 8/20 0.39
CYP19A1 P11511 7/20 0.39
CYP1A2 P05177 6/20 0.39
CYP2D6 P10635 3/20 0.38
CYP3A4 P08684 1/20 0.37
CDC7 O00311 1/20 0.36
PLK4 O00444 1/20 0.36
CHEK1 O14757 1/20 0.36
CHUK O15111 1/20 0.36
PDPK1 O15530 1/20 0.36
DYRK3 O43781 1/20 0.36
ROCK2 O75116 1/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
PAK4 O96013 1/20 0.36
NTRK1 P04629 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5083217 0.95 SOAT1 (0.41) LTA4HBCHEACHECYP2C9CYP2C19
SCHEMBL4724824 0.92 MAPT (0.34) BCHEACHECYP2C19CYP1A2ALDH1A1
SCHEMBL4721792 0.86 KDM4E (0.41) LTA4HMAPK1ALDH1A1NPC1MAPT
SCHEMBL4767264 0.77 TSHR (0.38) ALDH1A1NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL4722707 0.76 CYP2C9 (0.41) LTA4HBCHEACHECYP2C9CYP2C19
SCHEMBL5083212 0.72 SOAT1 (0.41) LTA4HBCHEACHECYP2C9CYP2C19
SCHEMBL4724526 0.71 S1PR1 (0.38) MAPK1ALDH1A1GAANPC1MAPT
SCHEMBL4765647 0.70 CYP2C9 (0.46) LTA4HBCHEACHECYP2C9CYP2C19
SCHEMBL4722492 0.70 CYP2D6 (0.40) LTA4HCYP2C9CYP2C19CYP19A1CYP1A2
SCHEMBL4723122 0.70 SOAT1 (0.42) LTA4HBCHEACHECYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 LTA4H 70/4885BCHE 3103/4885ACHE 626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.